OPEN LABEL EXPLORATORY PHASE IIA TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF IFX-1 IN TREATING SUBJECTS WITH PYODERMA GANGRENOSUM

Registry ID

IFX-1-P.2.7

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

INFLARX GMBH

Start date

2019-04-25

Completion date

2020-06-25

Last update

2019-02-12

Conditions

• PYODERMA GANGRENOSUM

Related clinical trials

• A MULTI-CENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE BLIND, PARALLEL-GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF SPESOLIMAB (BI 655130) IN ADULT PATIENTS WITH ULCERATIVE PYODERMA GANGRENOSUM (PG) WHO REQUIRE SYSTEMIC THERAPY
• A 2-YEAR, OPEN-LABEL, SAFETY EXTENSION STUDY OF GEVOKIZUMAB IN SUBJECTS WITH PYODERMA GANGRENOSUM
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF GEVOKIZUMAB IN TREATING ACTIVE ULCERS OF PYODERMA GANGRENOSUM

View on source registry